Stay updated on Cabozantinib-Pemetrexed in Lung, Urothelial, Mesothelioma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib-Pemetrexed in Lung, Urothelial, Mesothelioma Clinical Trial page.

Latest updates to the Cabozantinib-Pemetrexed in Lung, Urothelial, Mesothelioma Clinical Trial page
- Check7 days agoChange DetectedPage revision updated from v3.6.3 to v3.6.4, indicating a software update. No study details or content appear to be affected.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedPage revision tag updated from v3.6.2 to v3.6.3, signaling a new build of the ClinicalTrials.gov page. This update does not appear to alter the study details or user-facing content.SummaryDifference0.1%

- Check36 days agoChange DetectedThe revision tag on the page was updated from v3.6.0 to v3.6.2, signaling a minor update to the page or its underlying system rather than a change to the study details.SummaryDifference0.1%

- Check50 days agoChange DetectedRecruitment status on the study page is updated to indicate no longer looking for participants, signaling that enrollment has ended. New guidance sections such as How to Read a Study Record, Common Questions, and How to Join a Study were added, and the page revision label was updated to v3.6.0 (replacing the previous v3.5.5).SummaryDifference0.6%

- Check57 days agoChange DetectedFooter revision updated from Revision: v3.5.4 to Revision: v3.5.5, indicating a minor site update that does not affect the study details.SummaryDifference0.1%

- Check79 days agoChange DetectedThe page revision tag was updated from v3.5.3 to v3.5.4, indicating a new revision of the study record metadata.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib-Pemetrexed in Lung, Urothelial, Mesothelioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib-Pemetrexed in Lung, Urothelial, Mesothelioma Clinical Trial page.